Lumos Diagnostics launches A$2m share purchase plan for eligible investors

Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.

Lumos Diagnostics Holdings Limited has launched a Share Purchase Plan offering eligible shareholders in Australia and New Zealand the opportunity to subscribe for up to A$30,000 of new shares at A$0.225 each, on the same terms as its recent placement. The offer includes one free-attaching unquoted option for every two shares subscribed, exercisable at A$0.34 and expiring on 31 December 2027.

The company is targeting up to A$2 million in proceeds from the plan, equivalent to a maximum of 8,888,889 shares and 4,444,444 new options, with the Board retaining discretion to scale back applications or accept oversubscriptions subject to regulatory limits. The Share Purchase Plan, which closes on 24 April 2026, is non-transferable and is intended to provide existing eligible shareholders with a convenient way to increase their holdings while supporting Lumos Diagnostics’ ongoing capital needs.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Limited is an Australia-based medical diagnostics company listed on the ASX under the ticker LDX. The company focuses on developing and commercialising diagnostic products and services, with a shareholder base primarily in Australia and New Zealand targeted through ASX-regulated capital management initiatives.

Average Trading Volume: 4,417,434

Technical Sentiment Signal: Buy

Current Market Cap: A$168.6M

For an in-depth examination of LDX stock, go to TipRanks’ Overview page.